HematologyNews.net

Hematology Xagena

Xagena Mappa
Medical Meeting
Neurobase.it
XagenaNewsletter

The results from the pivotal phase III GALLIUM trial in people with previously untreated follicular lymphoma, the most common type of indolent ( slow-growing ) non-Hodgkin lymphoma ( iNHL ), were anno ...


Despite new therapies, multiple myeloma remains incurable causing most patients to ultimately develop drug resistance and succumb to the disease. The pursuit of drugs that inhibit cell cycle regulator ...


Researchers at Boston University have shown that T-cell leukemia cells use a particular cycle, called the TCA or Kreb cycle, to support their growth and survival. The findings which appear in the j ...


A new analysis has indicated that higher body weight and taller stature during adolescence increase the risk of developing non-Hodgkin's lymphoma ( NHL ), a type of cancer of the lymphatic system. T ...


Mantle cell lymphoma ( MCL ) is an aggressive lymphoma with a dismal prognosis because of numerous relapses. Because the most promising results have been obtained with immunochemotherapy followed by ...


The results of the phase II TITAN study with Caplacizumab for patients with acquired thrombotic thrombocytopenic purpura ( aTTP) have been published in The New England Journal of Medicine ( NEJM ). ...


Positive results from the global phase III RATIFY ( CALGB 10603 ) clinical trial were announced. In the study, adult patients under 60 years of age with newly-diagnosed FLT3-mutated acute myeloid leuk ...


A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma ( DLBCL ) are more likely to respond to the drug Ibrutinib ( Imbruvica ) than patients with ...


The benefit of Azacitidine treatment in survival of high-risk myelodysplastic syndromes ( MDS ) patients compared with conventional care treatment ( CCT ) has not been established outside clinical tri ...


Results of a phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of Blinatumomab ( Blincyto ) in adults with relapsed or refractory Philadelphia chromosome-positive ( ...


A phase 2 trial of the investigational medicine Venetoclax met its primary endpoint ( overall response rates ) in patients with relapsed / refractory or previously untreated chronic lymphocytic leukem ...


PF-05082566 ( PF-2566 ) is an investigational immunotherapy and fully humanized monoclonal antibody administered intravenously that stimulates signaling through 4-1BB ( CD-137 ), a protein expressed i ...


Results from a sub-analysis of the phase 2 RESONATE-17 study has shown Ibrutinib ( Imbruvica ) was associated with robust efficacy and a positive risk-benefit profile in patients with relapsed or refr ...


Initial treatment of acute promyelocytic leukaemia traditionally involves Tretinoin ( all-trans retinoic acid ) combined with anthracycline-based risk-adapted chemotherapy, with Arsenic trioxide being ...


Ninety-three percent of pediatric patients ( 55 of 59 ) with relapsed/refractory acute lymphoblastic leukemia ( ALL ) went into remission after receiving an investigational therapy made from their own ...